Take Warren Buffett's Advice: Don't Buy Any Stock in 2026 Unless It Passes This Test

Referencing Warren Buffett's two-step investment test from his 2013 shareholder letter, the piece highlights AbbVie and Nucor as companies that appear to meet the criteria: AbbVie is cited for robust five-year earnings visibility, an attractive valuation and a 3% forward dividend yield as a Dividend King, while Nucor is noted for potential demand tailwinds from data-center construction and U.S. infrastructure spending and a forward P/E of 14.5. The article also notes Buffett has been a net seller for 12 consecutive quarters and Berkshire sits on a record cash position, underscoring a cautious macro positioning despite these individual opportunities.

Analysis

Market structure: The immediate beneficiaries are cash-rich, high-margins in healthcare (ABBV) and domestic steel producers with flexible mills (NUE) as data-center and U.S. infrastructure demand boost specialty and construction steel volumes. Competitors lacking differentiated pipelines or efficient mini-mill assets will face margin compression and share loss; expect integrated, commodity-focused steel names to underperform if HRC spreads narrow by >15% over 6–12 months. Cross-asset: stronger steel demand should lift HRC futures and industrial metals, supporting cyclical EM FX and commodity-linked credit spreads, while defensive flows (BRK cash hoard) pressure high-growth equity multiples and support longer-duration bonds in risk-off episodes.

Risk assessment: Key tail risks are AbbVie pipeline disappointments or faster-than-expected biosimilar Humira erosion (15–30% hit to EPS if severe), and a sharp demand pullback for steel from a recession that cuts construction and data-center capex by >20% within 12 months. Time horizons differ: intra-days-weeks react to earnings/FDA decisions; 1–6 months driven by infrastructure bill implementation and steel order books; 3–5 years hinge on AbbVie's M&A/pipeline and secular steel capacity. Hidden dependencies include interest rates (capital costs for buybacks/M&A) and FX exposure for exporters; catalysts to watch: AbbVie Q1/Q2 guidance, key FDA reviews in next 90–180 days, U.S. ISM/industrial data monthly.

Trade implications: Tactical longs: establish 2–3% position in ABBV over 4–6 weeks, scaling in on >5% pullbacks or if forward dividend yield >3.2%; hedge downside by selling 1–2x 90-day covered calls 8–12% OTM to boost carry. For NUE, initiate 1.5–3% long position and consider a pair trade long NUE / short X (U.S. Steel) sized 1:0.6 to express quality mill advantage; exit if NUE forward P/E >18 or HRC futures drop >15% from spot. Options: buy 9–12 month LEAPS on NUE as convexity play if steel spread normalization is anticipated; use 3–6 month protective puts on ABBV if FDA calendar shows material binary risk.

Contrarian angles: The consensus underestimates idiosyncratic downside for ABBV if biosimilars accelerate — market often misprices 18–24 month regulatory binary risk, creating opportunities to buy after a 12–15% overreaction. Conversely, NUE exposure may be priced for perpetual strength in infrastructure; historical steel cycles (2015–2016) show pricing can reverse quickly once capacity or import flows reassert. Unintended consequence: accelerated U.S. infrastructure could spur imports and new capacity, capping domestic steel margins—limit sizing and use stop-losses at 8–12% to protect from cycle reversals.

Key Decisions for Investors

• Establish a staggered 2–3% long position in ABBV (NYSE: ABBV) over the next 4–6 weeks; scale in on >5% pullbacks or if forward dividend yield rises above 3.2%; sell 90-day covered calls 8–12% OTM to generate premium while holding, and buy 3–6 month protective puts if an FDA decision falls within the window.
• Initiate a 1.5–3% long position in Nucor (NYSE: NUE) and implement a relative-value pair trade: long NUE / short U.S. Steel (X) at a 1:0.6 ratio to favor mini-mill quality; trim NUE if forward P/E breaches 18 or if HRC steel futures decline >15% from current levels.
• Buy 9–12 month LEAPS on NUE (~delta 0.60–0.70) sized for 0.5–1% portfolio risk as a convex way to play infrastructure-led steel demand; hedge ABBV downside with 3–6 month puts sized to cap portfolio drawdown at ~1% if binary regulatory risk increases.
• Reduce cyclical, commodity-steel exposure outside NUE by 20–30% vs. benchmark weight across the next quarter; re-allocate proceeds into high-quality healthcare (ABBV) and cash/IG duration until 1) AbbVie's next two earnings/FDA updates clear or 2) ISM manufacturing prints sustainably above 52 for three months indicating durable steel demand.